Updates are available Correction dated 2023-07-18
Click to view Correction: https://doi.org/10.1038/s41590-023-01591-1
-
Authors
Brightman, Spencer E.
Becker, Angelica
Thota, Rukman R. http://orcid.org/0000-0002-9225-9516
Naradikian, Martin S.
Chihab, Leila
Zavala, Karla Soria
Ramamoorthy Premlal, Ashmitaa Logandha
Griswold, Ryan Q.
Dolina, Joseph S.
Cohen, Ezra E. W.
Miller, Aaron M.
Peters, Bjoern http://orcid.org/0000-0002-8457-6693
Schoenberger, Stephen P. http://orcid.org/0000-0002-9870-7340
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (U01 DE028227)
- License Information
-
More Information
Article History
Received: 8 March 2023
Accepted: 22 May 2023
First Online: 3 July 2023
Change Date: 18 July 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41590-023-01591-1
Competing interests
: M.S.N., A.M.M., B.P. and S.P.S. are listed as inventors on patents related to tumor-specific TCRs. S.P.S. serves on the scientific advisory boards of Telesis Bio, 3T Biosciences and Grit Bio. All other authors declare no competing interests.
